文献速递认知障碍与痴呆

抗β-淀粉样蛋白免疫治疗阿尔茨海默病患者淀粉样蛋白相关影像学异常的发生率:一项Meta分析

Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis.
PubMed 文献 · Neurology · 2022-08-29

该Meta分析纳入19项研究(24个队列,9429例患者),评估抗β-淀粉样蛋白免疫治疗临床试验中淀粉样蛋白相关影像学异常(ARIA)的发生率。ARIA-积液(ARIA-E)和ARIA-出血(ARIA-H)的汇总发生率分别为6.5%和7.8%,无症状ARIA的汇总比例为80.4%。使用阿杜卡尼单抗治疗的队列ARIA-E和ARIA-H发生率(30.7%和30.0%)显著高于其他药物队列(均p<0.001)。

要点

  • ARIA-E和ARIA-H的汇总发生率分别为6.5%和7.8%,无症状ARIA比例为80.4%。
  • 阿杜卡尼单抗队列ARIA-E和ARIA-H发生率分别为30.7%和30.0%,显著高于其他药物。
  • ApoE-4携带者与非携带者ARIA发生率无统计学显著差异(ARIA-E 8.6% vs 6.9%,p=0.663)。

核心结论

  • ARIA-E和ARIA-H的总体发生率分别为6.5%和7.8%,无症状ARIA的汇总比例为80.4%。
  • 使用阿杜卡尼单抗治疗的队列ARIA-E和ARIA-H发生率(30.7%和30.0%)显著高于其他药物队列(均p<0.001)。

研究设计与样本

  • 检索PubMed和Embase数据库截至2022年1月12日发表的抗Aβ免疫治疗临床试验。
  • 纳入报告足够详细数据以评估ARIA发生率的2期或3期随机对照试验,共19项研究、24个队列、9429例患者。
  • 采用DerSimonian-Liard随机效应模型计算ARIA的汇总发生率,并按药物和ApoE-4携带状态进行亚组分析。

主要发现

  • ARIA-E和ARIA-H的总体汇总发生率分别为6.5%和7.8%。
  • 阿杜卡尼单抗队列ARIA-E和ARIA-H发生率分别为30.7%和30.0%,显著高于其他药物队列(均p<0.001)。
  • ApoE-4携带者组ARIA-E和ARIA-H发生率分别为8.6%和10.5%,非携带者组分别为6.9%和6.6%,差异均无统计学意义(ARIA-E p=0.663,ARIA-H p=0.398)。
  • 常规MRI监测发现的无症状ARIA汇总比例为80.4%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To assess the incidence of amyloid-related imaging abnormalities (ARIA) in clinical trials of anti-β-amyloid (Aβ) immunotherapy and compare the incidence among different agents and clinical characteristics to identify possible predisposing factors for ARIA. METHODS: The PubMed and Embase databases were searched for clinical trials of anti-Aβ immunotherapy published on or before January 12, 2022. Phase 2 or 3 randomized controlled trials reporting detailed data sufficient to assess the incidence of ARIA were selected. The pooled incidences of ARIA and subgroup analyses according to agent and ApoE-4 carrier status were calculated using the DerSimonian-Liard random-effects model. The proportion of symptomatic ARIA cases was also calculated. RESULTS: In total, 19 eligible studies, including 24 cohorts, were identified and 9,429 patients were analyzed. The overall pooled incidence of ARIA-effusion (E) and ARIA-hemorrhage (H) was 6.5% and 7.8%, respectively. In the subgroup analysis, the incidence of ARIA was different according to the anti-Aβ immunotherapy agent. The cohorts treated with aducanumab had a significantly higher incidence of ARIA-E and ARIA-H (30.7% and 30.0%, respectively; both p < 0.001) compared with cohorts from other drugs. In subgroup analysis according to ApoE-4 carrier status, the incidences of ARIA-E and ARIA-H were higher in the ApoE-4 carrier group than those in the ApoE-4 noncarrier group, but there was no statistical significance (ApoE-4 carrier vs noncarrier, ARIA-E: 8.6% vs 6.9%, p = 0.663, and ARIA-H: 10.5% vs 6.6%, p = 0.398). The pooled proportion of asymptomatic ARIA, detected by routine scheduled MRI surveillances, was 80.4%. DISCUSSION: The overall incidences of ARIA-E and ARIA-H were 6.5% and 7.8%, respectively, and the pooled proportion of asymptomatic ARIA was 80.4%. The cohorts treated with aducanumab showed a significantly higher incidence of ARIA-E and ARIA-H (30.7% and 30.0%) compared with other drugs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Jeong SY, Suh CH, Shim WH, et al. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis. Neurology. 2022. PMID: 36038268. doi:10.1212/WNL.0000000000201019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。